These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1770228)

  • 1. Hybrid cytokines as hematopoietic growth factors.
    Williams DE; Park LS; Broxmeyer HE; Lu L
    Int J Cell Cloning; 1991 Nov; 9(6):542-7. PubMed ID: 1770228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.
    Vadhan-Raj S
    Stem Cells; 1994 May; 12(3):253-61. PubMed ID: 8075592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
    Anderson JE; Appelbaum FR
    Curr Opin Hematol; 1994 May; 1(3):203-9. PubMed ID: 9371283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-dependent ex vivo expansion of early subsets of CD34+ cord blood myeloid progenitors is enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored.
    Ruggieri L; Heimfeld S; Broxmeyer HE
    Blood Cells; 1994; 20(2-3):436-54. PubMed ID: 7538350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys.
    Williams DE; Dunn JT; Park LS; Frieden EA; Seiler FR; Farese AM; Macvittie TJ
    Biotechnol Ther; 1993; 4(1-2):17-29. PubMed ID: 8374510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
    Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
    Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of stem cell factor with interleukin-3 or granulocyte-macrophage colony-stimulating factor on the proliferation of murine primitive hematopoietic progenitors.
    Wu DD; Nayar R; Keating A
    Exp Hematol; 1994 Jun; 22(6):495-500. PubMed ID: 7514543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
    McCrady CW; Li F; Pettit GR; Grant S
    Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein.
    Curtis BM; Williams DE; Broxmeyer HE; Dunn J; Farrah T; Jeffery E; Clevenger W; deRoos P; Martin U; Friend D
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5809-13. PubMed ID: 1829529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-kit ligand augments granulocyte-macrophage colony growth from patients with 5q- syndrome.
    Rosenfeld CS; Nemunaitis J; Sherer CR; Zeigler ZR; Shadduck RK
    Stem Cells; 1993 Nov; 11(6):562-7. PubMed ID: 7509225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
    Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
    Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors.
    Ottmann OG; Abboud M; Welte K; Souza LM; Pelus LM
    Exp Hematol; 1989 Feb; 17(2):191-7. PubMed ID: 2463933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
    Izquierdo MA; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff DD
    Clin Cancer Res; 1996 Oct; 2(10):1713-6. PubMed ID: 9816121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between different high proliferative potential colony-forming cells in mouse bone marrow.
    Kriegler AB; Verschoor SM; Bernardo D; Bertoncello I
    Exp Hematol; 1994 May; 22(5):432-40. PubMed ID: 7513652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
    Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C; Hittelman WN; McAlister I; Garrison L; Williams DE
    Blood; 1995 Sep; 86(6):2098-105. PubMed ID: 7662957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth response of Lin-Thy-1+ hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors.
    Jacobsen SE; Ruscetti FW; Ortiz M; Gooya JM; Keller JR
    Exp Hematol; 1994 Sep; 22(10):985-9. PubMed ID: 7522186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
    Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
    Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro and in vivo effects of stem cell factor on human hematopoiesis.
    Hoffman R; Tong J; Brandt J; Traycoff C; Bruno E; McGuire BW; Gordon MS; McNiece I; Srour EF
    Stem Cells; 1993 Jul; 11 Suppl 2():76-82. PubMed ID: 7691331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.